Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ixekizumab with randomized treatment-withdrawal and retreatment in axial spondyloarthritis
MOH_2017-04-20_000181Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in axial spondyloarthritis (axSpA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Primary objective. Started Feb 2017; status: active, not recruiting.
02
Drugs
ixekizumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on MOH_2017-04-20_000181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-20_000181.